Akari Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Akari Therapeutics (AKTX).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$32Upside to Avg. PT+304.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 20, 2026	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$30
Apr 8, 2026	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Apr 1, 2026	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$2→$27
Jan 5, 2026	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$40
Sep 9, 2025	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$64
Jul 18, 2025	Maxim Group	Jason McCarthy	Initiate	Buy	$200

Analyst Ratings News

PRO
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Akari Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

HC Wainwright & Co. analyst Sean Lee reiterates Akari Therapeutics (NASDAQ:AKTX) with a Buy and maintains $1.6 price target.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $5.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

Benzinga Insights

PRO
HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.

Benzinga Newsdesk

Akari Therapeutics PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Akari Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

PRO
Maxim Group Downgrades Akari Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

PRO
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

PRO
HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5

People Also Watch

People Also Watch

Akari Therapeutics PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Akari Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

PROMaxim Group Downgrades Akari Therapeutics to Hold

PROHC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

PROMaxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

PROHC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5

People Also Watch

People Also Watch

PRO
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

PRO
Maxim Group Downgrades Akari Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

PRO
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

PRO
HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5